Retatrutide, from Soma Pharmaceuticals , is receiving considerable attention as a innovative treatment for metabolic control . This unique drug merges the properties of a GLP-1 receptor activator and a GIP receptor activator , designed to effectively promote weight loss but also address related metabolic factors. Initial human data have demonstrate